The notices it replaced
- Reissues: PAR-24-115 NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- 2 steps back: PAR-20-216 NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)
- 3 steps back: PAR-18-125 NCCIH Natural Product Phase II Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)
- 4 steps back: PAR-17-216 NCCIH Natural Product Phase II Clinical Trial Cooperative Agreement (U01)
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,161,412 in first-year total cost, median $580,706.
Most frequent study sections
- Special Emphasis Panel[ZAT1 SH (11)]1
- Special Emphasis Panel[ZAT1 SH (15)]1
Most frequent institutions
- BRIGHAM AND WOMEN'S HOSPITAL1
- SLOAN-KETTERING INST CAN RESEARCH1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping1R01AT013147-01 · under PAR-24-115 | FLAUMENHAFT, ROBERT CJEWELL, ELIZABETHZWICKER, JEFFREY | SLOAN-KETTERING INST CAN RESEARCH, NY | $631,382 | ZAT1 |
| 2024 | Cocoa Flavanols for Migraine: A Pilot Study1U01AT012611-01 · under PAR-20-216 | RIST, PAMELA M. | BRIGHAM AND WOMEN'S HOSPITAL, MA | $530,030 | ZAT1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.